Exclusive-Medicaid Fuels US Coverage of Novo, Lilly Weight-Loss Drugs
State Medicaid programs for low-income families are the single biggest source of coverage, giving 31.6 million people access ...
ENDPOINTS NEWS47 分钟
Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?
Patients who would benefit from a GLP-1 face significant challenges when it comes to access. Shortages have made it difficult ...
Medicaid fuels US coverage of Novo, Lilly weight-loss drugs
State Medicaid programs for low-income families are the single biggest source of coverage, giving 31.6 million people access to Novo Nordisk's Wegovy or Eli Lilly's Zepbound, according to the AXIACI ...